Objective: Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and is associated with a high risk of stroke. The efficacy and safety of catheter ablation in this setting is poorly characterised. We aimed to systematically review the existing literature and to perform a meta-analysis to determine the efficacy and safety of catheter ablation of AF in patients with HCM.
Background
Hypertrophic cardiomyopathy (HCM) is the most frequent monogenic cardiovascular disease affecting 1 out of every 500 individuals in the general population [1] . Atrial fibrillation (AF) is the most common arrhythmia in patients with HCM with a prevalence and annual incidence 22.5% and 3.1%, respectively [2] . New-onset AF is often associated with heart failure symptoms [3] and requires prompt treatment with direct current cardioversion in haemodynamically unstable patients or ventricular rate control with oral ß-blockers or nondihydropyridine calcium channel antagonists followed by elective cardioversion [4] . There are no randomized controlled trials examining the effect of anti-arrhythmic drugs on long-term prevention of AF in patients with HCM and results in observational studies are conflicting [5] [6] [7] .
Similarly, studies assessing the impact of catheter ablation of AF in patients with HCM are sparse and provide contradictory results. The joint Heart Rhythm Society / European Heart Rhythm Association / European Cardiac Arrhythmia Society expert consensus statement on catheter ablation suggests that registries could facilitate the collection of more robust information on the safety and efficacy of AF ablation in the setting of less common underlying conditions, such as HCM [8] .
The aim of this study is to systematically review the existing literature and to perform a metaanalysis of observational studies to determine the efficacy and safety of catheter ablation of AF in patients with HCM.
Methods

I -Study Selection
We performed a search in the databases MEDLINE, EMBASE and COCHRANE (from inception to the 7 th July 2015) using the following search string: "catheter ablation" AND "hypertrophic cardiomyopathy" AND "atrial fibrillation". Reference lists of all accessed full-text articles were searched for sources of potentially relevant information. Ongoing studies assessing the outcomes of catheter ablation of AF in patients with HCM were searched on ClinicalTrials.gov, and experts in the field were contacted to ensure that all important studies had been included.
Authors of full-text papers and congress abstract authors were also contacted by email to retrieve additional information.
The population, intervention, comparison and outcome (PICO) approach was used for conducting the meta-analysis [9] . The population of interest included patients with HCM and the intervention was catheter ablation of AF. Comparisons were performed between HCM and controls (patients without HCM undergoing catheter ablation of AF). The outcomes were midterm procedural success, need of anti-arrhythmic drugs after successful ablation, number of catheter ablation procedures, and procedural complications.
Procedural success was defined as freedom from AF or atrial tachycardia relapse, with ECG documentation, after a blanking period. Procedural complications included in the analysis were thromboembolic events (including stroke and transient ischemic attack), pericardial tamponade requiring pericardiocentesis or pericardial effusion causing hemodynamic imbalance and necessitating prolonged monitoring, pulmonary vein (PV) stenosis, atrioesophageal fistula and procedure-related death occurring in the first 30 days post-procedure.
To meet inclusion criteria, studies were required to provide information on age, gender, and AF type (i.e. paroxysmal, persistent or permanent).
Studies providing no information regarding follow-up duration, and number of events in each group were excluded. Similarly, studies consisting of catheter ablation of the atrioventricular node or surgical ablation, and conference abstracts not published as full-text articles in the five years following to presentation were not examined. Studies presenting data in HCM patients but not in controls were included in the systematic review, but excluded from the metaanalysis.
Search results were reviewed and consensus reached by three investigators (RP, KP, and GB) to ensure that all studies met the pre-specified inclusion criteria.
Study quality was formally evaluated using a modified Newcastle-Ottawa Quality Assessment
Scale for Cohort Studies [10] by three reviewers (RP, KB and NS). An agreement between these three reviewers was mandatory for the final classification of studies.
II -Data Extraction
Data extraction and presentation for the preparation of this manuscript followed the recommendations of the PRISMA group [11] . From each study, we retrieved study design, study population characteristics (age range, gender and AF type, mitral regurgitation, left ventricular outflow tract obstruction, previous myectomy or septal ablation), follow-up duration, lesion set used in the ablation procedure, definition of relapse, post-procedural monitoring, use of anti-arrhythmic agents after blanking, predictors of relapse, midterm outcomes, and procedural complications
Comparisons between HCM and non-HCM patients were performed using odds ratio (OR), or mean difference when appropriate, and respective 95% confidence intervals were shown.
Outcomes were maintenance of sinus rhythm after one catheter ablation procedure, or after one or more catheter ablation procedures, number of ablation procedures, need of antiarrhythmic drugs following a successful ablation, and procedural complications. Weights of each study in forest-plots were calculated using the inverse variance method. Sensitivity analyses were performed excluding data from studies published only as conference abstracts for left atrial size, prevalence of individuals with persistent AF and left atrial size (comparison of studies below vs. above median level for the last two scenarios).
Statistical heterogeneity on each outcome of interest was assessed and quantified using the I 2 statistic, which describes the percentage of total variation across studies due to heterogeneity rather than chance. Values below 25%, between 25% and 50% and higher than 50% are, by convention, classified as low, moderate, and high degrees of heterogeneity, respectively [12] .
Funnel plots and meta-regression analyses were not performed as part of the assessment for the presence of publication bias, and possible association of baseline differences with modulator variables in procedural outcomes, respectively, as comparisons involved less than 10 studies, which is the minimum number for assuring the appropriateness of these methods [13] .
Results
I. Search Results
A total of 209 entries were retrieved for analysis of titles and abstracts. Of these, 177 were excluded as they were either duplicates or deemed unsuitable for the purpose of the metaanalysis (editorials, letters, reviews or case reports). The remaining 32 studies were carefully screened and after analysis of their abstracts and/or full-text only [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (one was a conference abstract [22] ) were considered adequate for inclusion in the systematic review ( Figure 1 ). Of these, only six studies [16, 19, [22] [23] [24] [25] provided enough details to be included in the meta-analysis. There was full agreement between investigators (RP, KP and GB) on the inclusion of the selected studies.
II. Baseline Data: Patients with HCM undergoing catheter ablation of AF
The design of selected investigations and baseline data are summarized in Tables 1 and 2 . The final population of the systematic review included 403 patients with HCM; 139 patients with HCM and 393 controls were included in the meta-analysis. All included studies were observational and nonrandomised, and only 5 were prospective [16, 17, 20, 21, 25] . Four studies were multi-centre [14, 15, 18, 21] .
Quality assessment of the included studies is shown on Table 3 . Study quality was modest, with only two studies [16, 23] being assigned 7 out of 9 possible points with the NewcastleOttawa scale.
The median HCM cohort size was 27 patients (IQR 22-39.5). Only one observational study included more than 50 patients with HCM [18] . In the 6 studies included in the meta-analysis, treatment groups were balanced for all baseline variables (Tables 1 and 2 patients [18] and one provided no diagnostic criteria for diagnosing HCM [22] .
Median age was 57 years (IQR 54-59). Women accounted for the minority of the HCM patients, with a median prevalence of 30% (interquartile range -IQR -26-33%). Persistent AF was the most common AF type in seven studies [19] [20] [21] [23] [24] [25] [26] . The median prevalence of nonparoxysmal AF was 53% (IQR 37-69%) ( Table 1 ).
In studies reporting time since AF diagnosis [14-18, 20,21, 23, 26, 27] , the median duration was 5.9 years (IQR 4.0-6.9). Median left atrial size was 47mm (IQR 46-51mm) and median maximum left ventricular thickness was 18mm (IQR 18-21mm). Only 9 studies reported on mitral regurgitation, and this was reported as moderate in 7 to 36% of patients in 6 out of the 9 studies reporting on this variable. The presence of left ventricular outflow tract obstruction at baseline and previous myectomy or alcohol septal ablation were reported in 11 [14] [15] [16] [17] [18] [19] [20] [23] [24] [25] [26] ] and 6 studies [14-16, 18, 19, 22, 24, 26] respectively, and had a median prevalence of 24%
(IQR 20-37.5%) and 14.5% (IQR 1.8-28.8%) ( Table 1 ).
III. Procedural data
All AF ablation procedures consisted of PV isolation and used radiofrequency as the energy source. In two studies [14, 15] , the PVs were the only targeted structures, but in the remainder ablation lines were created in the left atrium and/or right atrium, or lesions deployed to terminate atrial tachycardias (Table 2 ). Ostial PV isolation was performed in two publications [17, 20] , while in the remainder further ablation was performed in a more antral location. In three studies, complex atrial fractionated electrogram ablation was also performed [19] [20] [21] .
IV. Procedural outcomes
The median follow-up was 1.8 years (IQR 1.05-3.30 years). Except for three studies [14, 15, 25] , mean follow-up duration was greater than one year (Table 4) . In two studies, mean/median follow-up was greater than 3 years [18, 21] . Definition of relapse and monitoring post-ablation across all studies are described in Table 5 .
In four studies, freedom from AF (no documentation of further AF episodes after ablation) at the end of follow-up and after ≥ 1 procedure was 70% or greater [14, 15, 21, 23] . In two studies, this figure was 60% [16, 18] and in all remaining studies success rate was lower, in spite of several repeat ablation procedures. In two studies, patients remained in sinus rhythm free from anti-arrhythmic drugs [21] , or these were used in only a minority of patients [22] . However, in the remaining studies, antiarrhythmic agents were needed for optimisation of the rhythm control strategy in more than 25 to 50% of HCM patients. In controlled studies, chances of remaining on anti-arrhythmic drugs following a successful ablation were five-fold higher in HCM patients: OR=4.70, 95%CI
2.31-9.55, P<0.0001, I 2 =0% ( Figure 3 ). Of note, in some HCM patients these drugs were used because of concomitant ventricular arrhythmias.
V. Predictors of Procedural Success
Left atrial size was the most frequently identified predictor of procedural success [17, 18, [24] [25] [26] [27] . In two studies, persistent AF was also associated with worse procedural outcomes (OR=7.7, 95%CI 1.13-50, P=0.02 [20] and OR=2.58, 95%CI 1.11-6.05, P=0.028 [21] ). Other predictors of relapse were identified separately in single studies: age and NYHA class [18] , left atrial pressure and left ventricle outflow tract obstruction [24] , AF duration in months and E/E' [25] , and QTc duration [27] (Table 4) .
VI. Sensitivity Analyses
Sensitivity analysis after excluding results published as a conference abstract [22] Funnel-plots and meta-regression were not performed, as only 6 entries were eligible for the meta-analysis.
VII. Complications of AF ablation
While six studies reported no major complications, thromboembolic complications without permanent sequels occurred in two studies [17, 20] (Table 5) . PV stenosis was reported in three entries, ranging from 3.0% [17] and 4.5% [25] to 4.8% [15] . Contreras-Valdes and colleagues reported that HCM patients may have longer post-ablation hospitalisation and higher readmission rate at 30 days, at the expense of heart failure and congestive symptoms [24] .
Due to the low incidence of major complications, no forest-plots could be created as no comparisons were possible between HCM and controls.
Discussion
This systematic review demonstrates that the success rate of AF ablation is lower in patients with HCM than in patients without HCM with an overall efficacy of AF ablation in HCM at least Given these major factors limiting success, it is remarkable that after a median of 1.4
procedures, the success rate is 52%. These data would suggest that if AF can be treated earlier in the natural history of the disease before it becomes established, then the success rates may be higher but this has to be balanced against the degree of left atrial dilation on initial presentation and degree of mitral regurgitation and LV diastolic dysfunction affecting the likelihood of at least medium-term success. Indeed the challenge remains to identify those patients who are most likely to benefit from ablation in the context of their HCM status and disease course. The high use of long term anti-arrhythmic drugs highlights the fact that ongoing remodelling limits the efficacy of ablation but should not be seen as a "failure" of the procedure since an combined treatment approach may be successful in these complex patients.
A number of structural and mechanistic factors further impact on the success rates of AF ablation in HCM. HCM patients have a high prevalence of atrial fibrosis, which may serve as a substrate for slow conduction and intra-atrial reentry, thereby playing a crucial role in the development and maintenance of AF [37, 38] . Sarcomeric gene mutations account for 60% of HCM cases. The β-MHC missense mutation Arg663His has been associated with an increased risk of AF in HCM patients with 47% Arg663His carriers developing AF over a seven-year followup period [39] . Polymorphisms in the angiotensin receptor gene have also been implicated in the development of AF in HCM [40] . Anatomic variations in left atrial thickness have been suggested [24] . However, preliminary data from Hayashi et al using computed tomography to measure left atrial thickness in a small sample of patients indicate that left atrial wall in HCM is no thicker than in matched patients without structural heart disease [23] .
Abnormal calcium handling is a recognized pathophysiological mechanism in HCM and could account for triggered activity (from delayed after depolarisations) precipitating AF in the proarrhythmic myocardial tissue architecture [41] .
Myocardial ischemia [42] and autonomic dysfunction [43] are two other factors that have been previously suggested as relevant triggers of AF, and may make AF ablation more difficult in the context of HCM.
Clearly, understanding the pathophysiology of AF in HCM and identifying predictors of relapse remain important to improve overall procedural outcomes. Santangelli et al. have suggested that these patients present with frequent non-PV triggers, which may be responsible for late recurrences [21] . These authors have favoured extensive ablation beyond PV isolation.
However, as we demonstrate in this review a consensus on the optimal approach for AF ablation in HCM patients remains elusive. It is unclear if performing PV isolation and targeting sustained atrial tachycardias is superior to employing a more aggressive approach with extensive lesion sets including lines, targeting complex fractionated electrograms and non-PV triggers in both atria. This is particularly important as even the optimal strategy to identify these sites and their relevance in procedural outcomes is contentious [44] . Furthermore, the optimal energy source to utilise is also not clear as all studies in this review have been performed using radiofrequency ablation. A randomized controlled trial to address this matter would be of interest.
Although the incidence of major complications was low and comparable to the general population, cases of PV stenosis, most of them asymptomatic, have been noted (ranging from 3 to 4.8%). In two reports these occurred in the setting of non-ostial PV isolation [15, 25] . As pulmonary venogram was not routinely performed in all cases we cannot report on the prevalence of this complication and this reflects the Registry data in the general AF ablation populations as asymptomatic PV stenosis is not reported routinely [45] .
Given the small numbers of patients in all included studies, it is unclear if the apparently high rate of PV stenosis truly reflects a higher risk in this population or if it is a product of small sample sizes in the reporting studies [15] . It has been suggested by Killicaslan et al. that patients with HCM might be prone to more exaggerated hypertrophic tissue responses leading to tissue stenosis [15] . This is yet to be confirmed, but it may also be a contributory factor for more frequent gap formation and PV reconnection in the HCM population. The possible increase in PV stenosis in this subset of patients warrants clarification, and the electrophysiologist performing cases in these patients should be aware of this potential complication and try to deliver lesions as far away as possible from the PVs.
Two systematic reviews on the role of catheter ablation of AF in HCM patients have been recently published [46, 47] . However, unlike these, where the overall success rate of the procedure is reported, ours is the first meta-analysis with a case-control design. This is of importance, as it is the first paper allowing comparisons between HCM patients vs. other patients undergoing AF ablation, providing a better understanding of the true effectiveness of the catheter ablation in this setting. As included studies in the aforementioned systematic reviews [46, 47] span for almost a decade, simply pooling the success rates in those cohorts of HCM patients without having any control group/comparator, makes the pooled odds ratio impossible to interpret.
Limitations
There are some limitations to this meta-analysis. First, there is a paucity of data and studies allowing the comparison of HCM and non-HCM patients. As a result of the included small number of studies and patients this analysis has low power. However, these data are able to demonstrate differences in outcomes of catheter ablation of AF in HCM and non-HCM patients. Second, the rate of HCM patients to controls differs across studies. Third, moderate to high heterogeneity was observed across the included studies. A careful analysis of Figures 2   and 3 , shows that the rate of relapse and number of redo procedures in HCM patients stands out as higher in the cohort published by McCready et al. [19] . This can be attributable to the fact that all patients in that study had persistent AF, and in most circumstances this was longstanding persistent. Lastly, data quality was modest, with no data derived from randomised controlled trials or large registries. The abovementioned factors suggest that the reliability of the estimated effect sizes may be sub-optimal.
Conclusions
Data regarding catheter ablation of AF in the HCM population is scarce and of modest quality.
The observed complication rate was low. Although outcomes seem less favourable than for the general population, with a two-fold higher risk of relapse, more frequent need of repeat procedures and concomitant use of anti-arrhythmic drugs, ablation can be a valuable option for symptomatic drug-refractory HCM patients, particularly in those with paroxysmal AF and smaller atria. Legend: AADs -anti-arrhythmic drugs; HCM -hypertrophic cardiomyopathy. Ostial PVI + CTI line ± mitral isthmus, roof line and CFAE ablation at the discretion of the operator 1.4 2 nd procedure: 43% (13) 16 patients with no AF/AT relapse at 12 months were under AADs and these were stopped in 5 pts.
Santangeli et al 2013 [21] All pts: PVI + posterior wall isolation between PVs. + SVC isolation Persistent AF: + all posterior wall (CS and left side of septum) + CFAE (LA and CS)
Redo: + non-PV triggers 
